News roundup Tuesday, January 21

The latest from BioStock

» Recruitment halfway through – Lipidor expects results in April
» Positive results for Xsprays XS003
» 304 million to take Gesynta Pharma through phase II
» Alzinova CEO: “Our clinical data was received with great enthusiasm at JPM”
» Prolight Diagnostics comments on acquisition of competitor

Read the newsletter for v.3 here.

The latest news

presents the first clinical results from iTANK-armed CAR T-cell therapy at the Cancer Crosslinks conference in Oslo. Read more.

Xspray Pharma reports strong interim data for product candidate XS003 and confirms plan to apply for market approval in H1 2025. Read more.

PharmaLundensis publishes positive results in animal toxicology tests with Phal-501. Read more.

Lipidor announces that half of the patients have been recruited to the ongoing phase III study. Read more.

AlzeCure gets abstract about NeuroRestore ACD856 accepted at the Alzheimer's conference AP/PD 2025. Read more.

AcuCort publishes supplementary prospectus. Read more.

Redsense Medical has completed user testing. Read more.

Proby applies for delisting and calls an extraordinary general meeting. Read more.

4basebio and Circio has entered into a collaboration to develop and test circVec synthetic DNA vectors for use in genetic medicine and vaccines. Read more.

Alzinova announces that the company's participation at the JP Morgan Healthcare Conference was successful. Read more.

Diamyd Medical granted a patent in South Korea. Read more.

Gabather has determined the subscription price for the exercise of warrants of series TO 6. Read more.

Peptonic Medical has decided to extend the subscription period in the ongoing rights issue. Read more.

Immunovia announces the outcome of the exercise of warrants series TO 2. Read more.

Arjo appoints Christofer Carlsson as acting CFO. Read more.

Communiqué

Integral

This morning's price development